These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 1623639)
1. Symbiotic relationship between a research institute and a pharmaceutical company: the Baker Institute/Glaxo Australia story. Angus JA Clin Exp Pharmacol Physiol; 1992 Jan; 19(1):67-71. PubMed ID: 1623639 [TBL] [Abstract][Full Text] [Related]
3. Interactions between physicians and the pharmaceutical industry: what does the literature say? Lexchin J CMAJ; 1993 Nov; 149(10):1401-7. PubMed ID: 8221424 [TBL] [Abstract][Full Text] [Related]
4. The Institute for One World Health--a not-for-profit pharmaceutical company. Lundberg GD MedGenMed; 2005 Jan; 7(1):61. PubMed ID: 16369366 [No Abstract] [Full Text] [Related]
5. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415. Adis International Ltd Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590 [TBL] [Abstract][Full Text] [Related]
6. Government initiatives in the development of a pharmaceutical industry in Australia. Hirst CA Clin Exp Pharmacol Physiol; 1992 Jan; 19(1):57-61. PubMed ID: 1623637 [TBL] [Abstract][Full Text] [Related]
7. Reader's response to the webcast video editorial entitled "the institute for one world health--a not-for-profit pharmaceutical company". Tarzwell R MedGenMed; 2005 Feb; 7(1):34. PubMed ID: 16369339 [No Abstract] [Full Text] [Related]
8. [Current challenges for the pharmaceutical research industry]. Chalchat B Ann Pharm Fr; 1993; 51(1):16-25. PubMed ID: 8215118 [TBL] [Abstract][Full Text] [Related]
9. Legal and ethical obligations to conduct a clinical drug trial in Australia as an investigator initiated and sponsored study for an overseas pharmaceutical company. Beran RG Med Law; 2004; 23(4):913-24. PubMed ID: 15685926 [TBL] [Abstract][Full Text] [Related]
10. An analysis of the clinical development of drugs in Norway for the years 2000 and 2004: the influence of the pharmaceutical industry. Winther FO; Hole OP; Nitter-Hauge S Eur J Clin Pharmacol; 2007 Oct; 63(10):909-12. PubMed ID: 17673994 [TBL] [Abstract][Full Text] [Related]
11. AMRAD: the first 4 years. Grace JP Clin Exp Pharmacol Physiol; 1992 Jan; 19(1):63-6. PubMed ID: 1623638 [TBL] [Abstract][Full Text] [Related]
14. From academic laboratory to the market: Disclosed and undisclosed narratives of commercialization. Sapir A; Oliver AL Soc Stud Sci; 2017 Feb; 47(1):33-52. PubMed ID: 28195026 [TBL] [Abstract][Full Text] [Related]
15. NCI cooperative research and development agreements. Ivy SP Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):27-9. PubMed ID: 11204659 [TBL] [Abstract][Full Text] [Related]
16. [BASIC TRENDS IN SCIENTIFIC RESEARCH IN THE DEPARTMENT OF DRUG TECHNOLOGY AND GALENIC PREPARATIONS AT THE N. NARIMANOV AZERBAIJAN MEDICAL INSTITUTE]. ALIJEV RK Cesk Farm; 1963 Sep; 12():348-52. PubMed ID: 14089542 [No Abstract] [Full Text] [Related]
17. [Drug development costs are overstated by the industry]. Jeppsson A Lakartidningen; 2006 Mar 1-7; 103(9):663-4; discussion 664. PubMed ID: 16583545 [No Abstract] [Full Text] [Related]
18. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium. Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650 [TBL] [Abstract][Full Text] [Related]
19. Twenty five years of the National Academy of Medical Sciences of Ukraine - progress and priorities for future of radiation medicine and biology. Bazyka D Probl Radiac Med Radiobiol; 2017 Dec; 22():10-14. PubMed ID: 29286493 [TBL] [Abstract][Full Text] [Related]
20. Analysis of phase II studies on targeted agents and subsequent phase III trials: what are the predictors for success? Chan JK; Ueda SM; Sugiyama VE; Stave CD; Shin JY; Monk BJ; Sikic BI; Osann K; Kapp DS J Clin Oncol; 2008 Mar; 26(9):1511-8. PubMed ID: 18285603 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]